Praziquantel


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Schistosomiasis 20 mg/kg 4-6 hourly for 3 doses or 40-60 mg/kg as a single dose. Clonorchiasis; Intestinal fluke infections; Lung fluke infections; Opisthorchiasis 25 mg/kg tid at 4-6 hour intervals for 1-2 days or 40 mg/kg as a single daily dose.
Dosage Details
Oral
Clonorchiasis, Intestinal fluke infections, Lung fluke infections, Opisthorchiasis
Adult: 25 mg/kg tid at intervals of 4-6 hour for 1-2 days or 40 mg/kg as a single dose.
Child: ≥4 year Same as adult dose.

Oral
Schistosomiasis
Adult: 20 mg/kg 4-6 hourly for 3 doses or 40-60 mg/kg as a single dose.
Child: ≥4 year Same as adult dose.
Administration
Should be taken with food. Swallow whole, do not chew/crush.
Contraindications
Ocular cysticercosis. Concomitant admin of strong CYP inducers (e.g. rifampicin). Lactation.
Special Precautions
Patient w/ cardiac abnormalities, cerebral cysticercosis, history of epilepsy and/or other signs of potential CNS involvement (e.g. subcutaneous nodules suggestive of cysticercosis). Moderate to severe hepatic impairment. Pregnancy.
Adverse Reactions
Headache, drowsiness, dizziness, malaise, abdominal discomfort, anorexia, nausea, vomiting, diarrhoea, urticaria, rash, fever, asthenia, malaise, fatigue, myalgia. Rarely, seizures, eosinophilia, pruritus, raised liver enzyme values.
Patient Counseling Information
This drug may cause dizziness or drowsiness, if affected, do not drive or operate machinery during or 24 hr after treatment.
MonitoringParameters
Monitor LFTs; patients w/ cardiac irregularities during therapy; monitor for seizures; culture urine or faeces for ova prior to treatment.
Drug Interactions
CYP enzyme-inducing drugs (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin) may decrease plasma concentrations of praziquantel. CYP enzyme inhibitors (e.g. cimetidine, erythromycin, itraconazole, ketoconazole) may increase plasma concentrations of praziquantel.
Potentially Fatal: Concomitant use w/ rifampicin may cause subtherapeutic concentrations of praziquantel.
Action
Description: Praziquantel is a pyrazinoisoquinoline anthelmintic agent w/ a broad spectrum of activity against trematodes (flukes) and cestodes (tapeworms). It increases the cell permeability to Ca in schistosomes, causing strong contractions and paralysis of worm musculature leading to detachment of suckers from the blood vessel walls and to dislodgement.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract (>80%). Time to peak plasma concentration: 1-4 hr.
Distribution: Distributed into the CSF and enters breast milk. Plasma protein binding: Approx 80%.
Metabolism: Undergoes rapid and extensive hepatic metabolism via hydroxylation by CYP2B1 and CYP3A4 isoenzymes to inactive metabolites.
Excretion: Via urine, mainly as metabolites. Plasma elimination half-life: Approx 1-1.5 hr (parent drug); approx 4 hr (metabolites).
Chemical Structure

Chemical Structure Image
Praziquantel

Source: National Center for Biotechnology Information. PubChem Database. Praziquantel, CID=4891, https://pubchem.ncbi.nlm.nih.gov/compound/Praziquantel (accessed on Jan. 23, 2020)

Storage
Store below 30°C.
MIMS Class
ATC Classification
P02BA01 - praziquantel ; Belongs to the class of quinoline derivatives and related substances used as antitrematodals.
References
Anon. Praziquantel. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/02/2016.

Biltricide Tablets (Bayer HealthCare Pharmaceuticals Inc.). U.S. FDA. https://www.fda.gov/. Accessed 17/02/2016.

Buckingham R (ed). Praziquantel. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/02/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Praziquantel. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 17/02/2016.

Disclaimer: This information is independently developed by MIMS based on Praziquantel from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in